CLINICAL-EPIDEMIOLOGICAL ANALYSIS OF HDL2 AND HDL3 SUBFRACTIONS IN ADULTS FROM MARACAIBO CITY, VENEZUELA

Objective: To carry out a clinical-epidemiological analysis of high-density lipoprotein cholesterol subfractions (HDL-C) in adults from Maracaibo, Venezuela. Materials and methods: A descriptive and cross-sectional study of the database from the Metbolic Syndrome Prevalence in Maracaibo Study was carried out. HDL3 and HDL2 serum concentration, as well as the HDL2/HDL3 ratio, were determined in 359 individuals of both sexes, over 18 years of age. Values obtained were evaluated according to sociodemographic, clinical and biochemical characteristics. Results: Mean population age was 39.4 ± 15.2 years, and 51.5% were female. Differences in HDL-C subfraction levels were only observed in those subjects with low HDL-C levels. Women with hypertriglyceridemia showed significantly lower serum HDL3 and HDL2 concentrations than those with normal triglycerides (p=0.033), as well as a lower HDL3 level and HDL2 / HDL3 ratio in those with higher levels of ultra-sensitive C-reactive protein (us-CRP) (p<0.001). A significantly lower concentration of HDL2 was observed in men with some degree of hypertension (p=0.031), insulin resistance (p=0.050) and metabolic syndrome (p=0.003); while those with elevated us-CRP showed a lower concentration of HDL3 (p=0.011). Conclusion: HDL-C subfractions show varying clinical-epidemiological behavior in adults from Maracaibo. Lower serum levels are observed in men, differences only in those with low HDL-C; and no predominance of any subclass was observed according to sociodemographic, clinical and biochemical characteristics.

[1]  M. Davidson The Battle of the HDL Subfractions. , 2019, Cardiovascular revascularization medicine : including molecular interventions.

[2]  Mohammad Hossein Khosravi,et al.  Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2018, Lancet.

[3]  I. Benseñor,et al.  Association between high-density lipoprotein subfractions and low-grade inflammation, insulin resistance, and metabolic syndrome components: The ELSA-Brasil study. , 2018, Journal of clinical lipidology.

[4]  A. M. Figueiredo Neto,et al.  Insulin Resistance Predicts Atherogenic Lipoprotein Profile in Nondiabetic Subjects , 2017, Journal of diabetes research.

[5]  Joselyn Rojas,et al.  HDL-C y riesgo de aterosclerosis , 2016 .

[6]  Kengo Moriyama,et al.  HDL2/HDL3 Ratio Changes, Metabolic Syndrome Markers, and Other Factors in a Japanese Population. , 2016, Journal of atherosclerosis and thrombosis.

[7]  Mervin Chávez-Castillo,et al.  Dysfunctional High-Density Lipoprotein: An Innovative Target for Proteomics and Lipidomics , 2015, Cholesterol.

[8]  E. Kabré,et al.  Reference Ranges of Cholesterol Sub-Fractions in Random Healthy Adults in Ouagadougou, Burkina Faso , 2015, PloS one.

[9]  J. López-Miranda,et al.  Epidemiologic Behavior and Estimation of an Optimal Cut-Off Point for Homeostasis Model Assessment-2 Insulin Resistance: A Report from a Venezuelan Population , 2014, International scholarly research notices.

[10]  S. Martin,et al.  High-density lipoprotein subfractions: current views and clinical practice applications , 2014, Trends in Endocrinology & Metabolism.

[11]  T. Hatsukami,et al.  HDL‐3 is a Superior Predictor of Carotid Artery Disease in a Case‐Control Cohort of 1725 Participants , 2014, Journal of the American Heart Association.

[12]  J. Salazar,et al.  Variations of Lipoprotein(a) Levels in the Metabolic Syndrome: A Report from the Maracaibo City Metabolic Syndrome Prevalence Study , 2013, Journal of diabetes research.

[13]  G. Norata,et al.  High-Density Lipoprotein Subfractions - What the Clinicians Need to Know , 2013, Cardiology.

[14]  T. Lüscher,et al.  Molecular mechanisms of vascular effects of High-density lipoprotein: alterations in cardiovascular disease , 2012, EMBO molecular medicine.

[15]  Paul T. Williams Fifty-three year follow-up of coronary heart disease versus HDL2 and other lipoproteins in Gofman's Livermore Cohort[S] , 2012, Journal of Lipid Research.

[16]  M. Velasco,et al.  The Maracaibo city metabolic syndrome prevalence study: design and scope. , 2010, American journal of therapeutics.

[17]  J. Cleeman,et al.  Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Forceon Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World HeartFederation; International Atherosclerosis Society; and International Asso , 2010 .

[18]  S. Grundy,et al.  Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International As , 2009, Circulation.

[19]  H. Tian,et al.  Alterations of high-density lipoprotein subclasses in hypercholesterolemia and combined hyperlipidemia. , 2007, International journal of cardiology.

[20]  J. Fragoso,et al.  Small HDL subclasses become cholesterol-poor during postprandial period after a fat diet intake in subjects with high triglyceridemia increases. , 2017, Clinica chimica acta; international journal of clinical chemistry.

[21]  P. Joshi,et al.  HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the Lipoprotein Investigators Collaborative. , 2015, European heart journal.

[22]  Milagros Rojas,et al.  The Maracaibo city metabolic syndrome prevalence study: primary results and agreement level of 3 diagnostic criteria , 2014 .

[23]  M. Velasco,et al.  High-sensitivity c-reactive protein epidemiological behavior in adult individuals from Maracaibo , Venezuela , 2013 .

[24]  Who Consultation on Obesity Obesity: preventing and managing the global epidemic. Report of a WHO consultation. , 2000, World Health Organization technical report series.

[25]  J. Gofman,et al.  Ultracentrifugal analysis of serum lipoproteins. , 1954, Methods of biochemical analysis.